CEO Update - 29 August 2023

I return from holiday to the news that Abcam, a key British life science company founded in 1998, is to be acquired by Danaher, bringing to a conclusion a headline-grabbing intervention this year by founder Jonathan Milner. Once again, this shows the global attractiveness of a global life science company built in the UK. Jonathan already has a track record for supporting the next-generation UK life science businesses and I hope he will continue to do so with some of the new proceeds from the sale.

10 drugs to face Medicare price negotiations 

The US today selected the first 10 drugs subject to Medicare price negotiations an important step in the development of the new legislation under the Inflation Reduction Act (IRA). If you need a refresher on why this matters for life science companies, take a look at the "IRA: Threats and opportunities for UK life sciences" webinar recording. This will remain a moving story, especially as there is a significant judicial challenge to the act in the US Court.

BIA Board Nomincations open

We are delighted to invite nominations from individuals interested in joining our BIA Board. Nominations for next year's board must be received by Friday, 15 September. This year, there are five places up for election for the corporate members and one for other members. If you’re interested in applying please contact company secretary, Nick Gardiner.

Steve Bates Headshot.png



Steve Bates OBE
CEO, BioIndustry Association

More news and updates

Macomics expands in Edinburgh, appoints Professor Paul Crocker to SAB

Macomics Ltd, a leader in macrophage drug discovery, continues its growth trajectory with expansion in Edinburgh into dedicated facilities within the Roslin Innovation Centre.

Evotec opens new state-of-the-art biology facility on Dorothy Crowfoot Hodgkin Campus

Evotec SE today celebrated the Grand Opening of a new facility, Building 95 (“B95”), on the Company’s Dorothy Crowfoot Hodgkin Campus at Milton Park.

MicrofluidX welcomes new board members and scientific advisor

MicrofluidX, a UK-based developer of technologies that streamline the development and deployment of cell and gene therapies, today announces the appointment of two new board members and an additional scientific advisor to support the company.

Eagle Genomics raises over £20 million and appoints new leadership

Eagle Genomics is pleased to announce it has raised additional financing of £3 million (USD $4 million) to further deploy its pioneering software platform that enables corporate customers to explore and monetise on microbiome-related research.

Laverock Therapeutics raises £13.5 million to develop gene silencing platform

Laverock Therapeutics announces it has expanded its seed funding round to £13.5 million, led by Calculus Capital with additional participation by Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos, UK Innovation & Science Seed Fund and Tekfen Ventures.

Dispatches from the party conferences – Liberal Democrats

In this first instalment of dispatches by the BIA team attending the conferences, Dr. Martin Turner, BIA's Head of Policy and Public Affairs, reports on what he’s heard from the Liberal Democrats.

More within